Overview

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Status:
Not yet recruiting

Trial end date:
2026-07-31

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

Phase:

Phase 3

Details

Lead Sponsor:

Hanmi Pharmaceutical Company Limited